Reports of Radiotherapy and Oncology

Published by: Kowsar

F-18 FDG PET-CT Influences Target Delineation When Combined With Standard CT-Based Radiotherapy Planning in the Palliative Setting in Malignant Pleural Mesothelioma; an Exploratory Study

Nicholas Mac Leod 1 , 2 , * , Jon Stobo 3 , Noelle O’Rourke 1 , Jonathan Hicks 1 , Karen Moore 1 , Marimuthu Sankaralingam 1 , 4 , Kurian Oommen 1 , Caroline Kelly 3 , Lynn McMahon 3 , Fat Wi Poon 5 , Sai Han 5 , Caroline Findlay 5 , Anthony Chalmers 1 , Marie Fallon 2 and Barry J. Laird 1 , 2
Authors Information
1 Beatson West of Scotland Cancer Centre, Glasgow, UK
2 Edinburgh Cancer Research Centre, University of Edinburgh, Edinburghs, UK
3 Cancer Research UK Clinical Trials Unit, University of Glasgow, Glasgow, UK
4 Department of Clinical Physics and Bioengineering, Beatson West of Scotland Cancer Centre, Glasgow, UK
5 West of Scotland PET-CT Centre, Gartnavel General Hospital, Glasgow, UK
Article information
  • Reports of Radiotherapy and Oncology: June 28, 2015, 2 (2); e3999
  • Published Online: June 12, 2015
  • Article Type: Research Article
  • Received: April 12, 2015
  • Accepted: May 28, 2015
  • DOI: 10.17795/rro-3999

To Cite: Mac Leod N, Stobo J, O’Rourke N, Hicks J, Moore K, et al. F-18 FDG PET-CT Influences Target Delineation When Combined With Standard CT-Based Radiotherapy Planning in the Palliative Setting in Malignant Pleural Mesothelioma; an Exploratory Study, Rep Radiother Oncol. 2015 ; 2(2):e3999. doi: 10.17795/rro-3999.

Copyright © 2015, Iranian Society of Clinical Oncology.This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Muers MF, Stephens RJ, Fisher P, Darlison L, Higgs CMB, Lowry E, et al. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. The Lancet. 2008; 371(9625): 1685-94
  • 2. Price A. What is the role of radiotherapy in malignant pleural mesothelioma? Oncologist. 2011; 16(3): 359-65[DOI][PubMed]
  • 3. Macleod N, Price A, O’Rourke N, Fallon M, Laird B. Radiotherapy for the treatment of pain in malignant pleural mesothelioma: A systematic review. Lung Cancer. 2014; 83(2): 133-8
  • 4. MacManus M, Nestle U, Rosenzweig KE, Carrio I, Messa C, Belohlavek O, et al. Use of PET and PET/CT for radiation therapy planning: IAEA expert report 2006-2007. Radiother Oncol. 2009; 91(1): 85-94[DOI][PubMed]
  • 5. Basu S, Saboury B, Torigian DA, Alavi A. Current evidence base of FDG-PET/CT imaging in the clinical management of malignant pleural mesothelioma: emerging significance of image segmentation and global disease assessment. Mol Imaging Biol. 2011; 13(5): 801-11[DOI][PubMed]
  • 6. Pehlivan B, Topkan E, Onal C, Nursal GN, Yuksel O, Dolek Y, et al. Comparison of CT and integrated PET-CT based radiation therapy planning in patients with malignant pleural mesothelioma. Radiat Oncol. 2009; 4: 35[DOI][PubMed]
  • 7. Vesselle H, Freeman JD, Wiens L, Stern J, Nguyen HQ, Hawes SE, et al. Fluorodeoxyglucose uptake of primary non-small cell lung cancer at positron emission tomography: new contrary data on prognostic role. Clin Cancer Res. 2007; 13(11): 3255-63[DOI][PubMed]
  • 8. Jena R, Kirkby NF, Burton KE, Hoole AC, Tan LT, Burnet NG. A novel algorithm for the morphometric assessment of radiotherapy treatment planning volumes. Br J Radiol. 2010; 83(985): 44-51[DOI][PubMed]
  • 9. Adli M, Kuzhan A, Alkis H, Andic F, Yilmaz M. FDG PET uptake as a predictor of pain response in palliative radiation therapy in patients with bone metastasis. Radiology. 2013; 269(3): 850-6[DOI][PubMed]
  • 10. Yildirim H, Metintas M, Entok E, Ak G, Ak I, Dundar E, et al. Clinical Value of Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography in Differentiation of Malignant Mesothelioma from Asbestos-Related Benign Pleural Disease. J Thorac Oncol. 2009; 4(12): 1480-4[DOI]
  • 11. Plathow C, Staab A, Schmaehl A, Aschoff P, Zuna I, Pfannenberg C, et al. Computed Tomography, Positron Emission Tomography, Positron Emission Tomography/Computed Tomography, and Magnetic Resonance Imaging for Staging of Limited Pleural Mesothelioma. Invest Radiol . 2008; 43(10): 737-44[DOI]
  • 12. Wilcox BE, Subramaniam RM, Peller PJ, Aughenbaugh GL, Nichols FC, Aubry MC, et al. Utility of Integrated Computed Tomography—Positron Emission Tomography for Selection of Operable Malignant Pleural Mesothelioma. Clin lung cancer. 2009; 10(4): 244-8
  • 13. Veit-Haibach P, Schaefer NG, Steinert HC, Soyka JD, Seifert B, Stahel RA. Combined FDG-PET/CT in response evaluation of malignant pleural mesothelioma. Lung Cancer. 2010; 67(3): 311-7[DOI][PubMed]
  • 14. Nestle U, Schaefer-Schuler A, Kremp S, Groeschel A, Hellwig D, Rube C, et al. Target volume definition for 18F-FDG PET-positive lymph nodes in radiotherapy of patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2007; 34(4): 453-62[DOI][PubMed]
  • 15. Lee ST, Ghanem M, Herbertson RA, Berlangieri SU, Byrne AJ, Tabone K, et al. Prognostic value of 18F-FDG PET/CT in patients with malignant pleural mesothelioma. Mol Imaging Biol. 2009; 11(6): 473-9[DOI][PubMed]
  • 16. Flores RM, Akhurst T, Gonen M, Larson SM, Rusch VW. Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2003; 126(1): 11-5
  • 17. Adams MC, Turkington TG, Wilson JM, Wong TZ. A systematic review of the factors affecting accuracy of SUV measurements. AJR Am J Roentgenol. 2010; 195(2): 310-20[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments